Global Cancer Treatment Market Share Grows at a Staggering CAGR of 9.63%

Introduction

Straits Research released its highly anticipated report, “Global Cancer Treatment Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 282.28 billion in 2025 and is projected to expand to USD 643.50 billion by 2034, registering a compound annual growth rate (CAGR) of 9.63%.

Market Dynamics

The market growth is attributed to the rising burden of cancer worldwide, expanding therapeutic innovations, rapid approval and adoption of novel therapies, and improved access to precision diagnostics. In addition, there exists a persistent unmet demand in oncology attributable to the rising incidence of cancer diagnoses. This draws cash inflows from both private investors and the government. Pharmaceutical conglomerates are expediting their pipelines via strategic acquisitions, while the government significantly invests in infrastructure and early-stage scientific research. In July 2025, Merck KGaA finalised the acquisition of SpringWorks Therapeutics, a biopharmaceutical firm specialising in severe rare diseases and cancer, for USD 3.4 billion. This dual approach mitigates development risks and accelerates commercialization timelines, hence ensuring continuous market growth. Moreover, hospitals now use simpler, faster tests on tumors and blood to find who will benefit from which medicine. When these tests spot the right signal or gene change, doctors can start the most effective drug sooner, often in earlier stages. Health systems are covering these tests more often, and regulators approve new drugs together with their tests, which speeds real-world use. This means more patients qualify, start treatment earlier, and stay on therapy longer, lifting demand for checkpoint drugs, targeted pills, antibody drug conjugates, and even cell and gene therapies across the cancer treatment market. 

Market Highlights

• Cancer Type: The Prostate cancer segment is estimated to grow at a CAGR of 10.63% during the forecast period.
• Product Type: The immuno-oncology checkpoint inhibitors segment dominated the market with a revenue share of 28% in 2025.
• End-User: The Research and academic centers segment is estimated to grow at a CAGR of 10.38%.
• Regional Insights: North America dominated the market with a 42.54% share, driven by growing local R&D capacity and rapid scaling of diagnostics and hospital infrastructure.

Competitive Players

1. Hoffmann-La Roche Ltd
2. Novartis AG
3. Pfizer Inc.
4. Merck & Co., Inc.
5. Bristol-Myers Squibb Company
6. AstraZeneca
7. Lilly USA, LLC
8. Johnson & Johnson
9. Amgen Inc.
10. Sanofi
11. Takeda Pharmaceutical Co.
12. Bayer AG
13. Astellas Pharma Inc.
14. Ipsen
15. BeiGene Ltd.
16. EsoBiotec
17. Zai Lab Ltd.
18. Everest Medicines
19. BioNTech
20. Serum Institute of India Pvt. Ltd
21. Others

Recent Developments

Segmentation

1. By Cancer Type (2026-2034)
   1. Breast Cancer
   2. Lung Cancer
   3. Colorectal Cancer
   4. Prostate Cancer
   5. Hematologic malignancies
   6. Pancreatic Cancer
   7. Ovarian Cancer
   8. Others
2. By Product Type (2026-2034)
   1. Cytotoxic chemotherapies
   2. Monoclonal antibodies
   3. Immuno-oncology checkpoint inhibitors
   4. Antibody-drug conjugates
   5. Cell & gene therapies
   6. Others
3. By End-User (2026-2034)
   1. Hospitals and cancer centers
   2. Research and academic centers
   3. Others